**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**



**SCHEDULE 13G**

**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND**

**AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)\***



**Verrica Pharmaceuticals Inc.**

**(Name of Issuer)**

**Common Stock, $0.0001 par value per share**

**(Title of Class of Securities)**

**9251 1W 108**

**(CUSIP Number)**

**December 31, 2021**

**(Date of Event which Requires Filing of this Statement)**



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* Rule 13d-1(b)
* Rule 13d-1(c)
  + Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



CUSIP No. 9251 1W 108 13G Page 2 of 5 Pages

* NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)



Matt Davidson

* CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) ☐ (b) ☐

* SEC USE ONLY
* CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5 SOLE VOTING POWER

|  |  |  |  |
| --- | --- | --- | --- |
| NUMBER OF |  | 560,731 |  |
| SHARES | 6 | SHARED VOTING POWER |  |
| BENEFICIALLY |  | 0 |  |
| OWNED BY |  |  |
| EACH | 7 | SOLE DISPOSITIVE POWER |  |
| REPORTING |  |  |  |
| PERSON |  | 560,731 |  |
| WITH |  |  |  |
| 8 | SHARED DISPOSITIVE POWER |  |
|  |  |

0

* AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

560,731

* 1. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

☐

* 1. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.04%1

* 1. TYPE OF REPORTING PERSON\* IN

1This percentage is calculated based upon 27,519,053 shares of the Issuer’s common stock outstanding as of November 4, 2021, as reported by the Issuer in its Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 12, 2021.



CUSIP No. 9251 1W 108 13G Page 3 of 5 Pages

**Item 1.**

1. Name of Issuer

**Verrica Pharmaceuticals Inc.**

1. Address of Issuer’s Principal Executive Offices

**10 North High Street, Suite 200 West Chester, PA 19380**

**Item 2.**

1. Name of Person Filing

**Matt Davidson**

1. Address of Principal Business Office or, if none, Residence

**4267 Valley Meadow Road Encino, CA 91436**

1. Citizenship

**Matt Davidson is a citizen of the United States of America.**

1. Title of Class of Securities

**Common Stock**

1. CUSIP Number

**9251 1W 108**

**Item** **3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:** NOT APPLICABLE.

1. ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
2. ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
3. ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
4. ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
5. ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
6. ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
7. ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
8. ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
9. ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
10. ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
11. ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

|  |  |  |  |
| --- | --- | --- | --- |
| CUSIP No. 9251 1W 108 | | 13G | Page 4 of 5 Pages |
| **Item 4.** | **Ownership.** |  |  |



Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

1. Amount beneficially owned: **See the responses to Item 9 on the attached cover page.**
2. Percent of class: **See the responses to Item 11 on the attached cover page.**
3. Number of shares as to which the person has:
   1. Sole power to vote or to direct the vote – **See the responses to Item 5 on the attached cover page.**
   2. Shared power to vote or to direct the vote – 0
   3. Sole power to dispose or to direct the disposition of – **See the responses to Item 7 on the attached cover page.**
   4. Shared power to dispose or to direct the disposition of – 0

**Item 5.** **Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

**Item 6.** **Ownership of More than Five Percent on Behalf of Another Person.**

**Not Applicable**

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

**Not Applicable**

**Item 8.** **Identification and Classification of Members of the Group.**

**Not Applicable**

**Item 9.** **Notice of Dissolution of Group.**

**Not Applicable**

**Item 10.** **Certifications.**

**Not Applicable**

CUSIP No. 9251 1W 108 13G Page 5 of 5 Pages

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

January 27, 2022

/s/ Matt Davidson



Matt Davidson